Introducing ai3Bio: Resetting the immune system at its root
Today, ai3Bio launched with $48M to directly target and eliminate disease-causing Th17 cells at their source, in a single step.
More than 15 million Americans live with autoimmune disease today, cycling through treatments that manage symptoms without ever reaching the source. ai3Bio was founded to change that.
Built to Move
Autoimmune Care Forward
Two Platforms. One Target: Pathogenic T Cells
LNP/mRNA Platform
A lipid nanoparticle delivers mRNA that triggers disease-causing T cells to self-destruct — precisely, in vivo, in one step.
Antibody Platform
A targeting antibody recruits the body's own immune cells to seek out and clear those same disease-causing T cells.
Jonathan Chow, Ph.D.
Director of Immunology
Dania Zhivaki, Ph.D.
Director, Discovery
Emily Gosselin, Ph.D.
Director, CMC
Sanjay Rathod, Ph.D.
Director, Antibody Discovery
Sreeram Balasubramanian, Ph.D.
Director, Computational Sciences
Director, Computational Sciences
